Literature DB >> 9653167

Poliovirus vaccine vectors elicit antigen-specific cytotoxic T cells and protect mice against lethal challenge with malignant melanoma cells expressing a model antigen.

S Mandl1, L J Sigal, K L Rock, R Andino.   

Abstract

Recombinant polioviruses expressing foreign antigens may provide a convenient vaccine vector system to induce protective immunity against diverse pathogens. Replication-competent chimeric viruses can be constructed by inserting foreign antigenic sequences within the poliovirus polyprotein. When inserted sequences are flanked by poliovirus protease recognition sites the recombinant polyprotein is processed to mature and functional viral proteins plus the exogenous antigen. It previously has been shown that poliovirus recombinants can induce antibody responses against the inserted sequences but it is not known whether poliovirus or vaccine vectors derived from it can elicit effective cytotoxic T lymphocyte (CTL) responses. To examine the ability of the recombinant poliovirus to induce CTL responses, a segment of the chicken ovalbumin gene, which includes the H2-Kb-restricted CTL epitope SIINFEKL, was cloned at the junction of the P1 and P2 regions. This recombinant virus replicated with near wild-type efficiency in culture and stably expressed high levels of the ovalbumin antigen. Murine and primate cells infected with the recombinant virus appropriately processed the SIINFEKL epitope and presented it within major histocompatibility complex class I molecules. Inoculation of mice with recombinant poliovirus that expresses ovalbumin elicits an effective specific CTL response. Furthermore, vaccination with these recombinant poliovirus induced protective immunity against challenge with lethal doses of a malignant melanoma cell line expressing ovalbumin.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9653167      PMCID: PMC20956          DOI: 10.1073/pnas.95.14.8216

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  48 in total

1.  Toward a poliovirus-based simian immunodeficiency virus vaccine: correlation between genetic stability and immunogenicity.

Authors:  S Tang; R van Rij; D Silvera; R Andino
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

Review 2.  Antigen processing and presentation by the class I major histocompatibility complex.

Authors:  I A York; K L Rock
Journal:  Annu Rev Immunol       Date:  1996       Impact factor: 28.527

3.  Antigen chimaeras of poliovirus as potential new vaccines.

Authors:  K L Burke; G Dunn; M Ferguson; P D Minor; J W Almond
Journal:  Nature       Date:  1988-03-03       Impact factor: 49.962

4.  Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains.

Authors:  T R Jones; E J Wiertz; L Sun; K N Fish; J A Nelson; H L Ploegh
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

5.  Engineering poliovirus as a vaccine vector for the expression of diverse antigens.

Authors:  R Andino; D Silvera; S D Suggett; P L Achacoso; C J Miller; D Baltimore; M B Feinberg
Journal:  Science       Date:  1994-09-02       Impact factor: 47.728

6.  The role of CD8+ T lymphocytes in coxsackievirus B3-induced myocarditis.

Authors:  A Henke; S Huber; A Stelzner; J L Whitton
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

7.  Evidence of presence of poliovirus genomic sequences in cerebrospinal fluid from patients with postpolio syndrome.

Authors:  I Leparc-Goffart; J Julien; F Fuchs; I Janatova; M Aymard; H Kopecka
Journal:  J Clin Microbiol       Date:  1996-08       Impact factor: 5.948

8.  Poliovirus-specific major histocompatibility complex class I-restricted cytolytic T-cell epitopes in mice localize to neutralizing antigenic regions.

Authors:  M Kutubuddin; J Simons; M Chow
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

9.  Antigen processing in vivo and the elicitation of primary CTL responses.

Authors:  N P Restifo; I Bacík; K R Irvine; J W Yewdell; B J McCabe; R W Anderson; L C Eisenlohr; S A Rosenberg; J R Bennink
Journal:  J Immunol       Date:  1995-05-01       Impact factor: 5.422

10.  Herpes simplex virus type 2 ICP47 inhibits human TAP but not mouse TAP.

Authors:  R Tomazin; N E van Schoot; K Goldsmith; P Jugovic; P Sempé; K Früh; D C Johnson
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

View more
  23 in total

1.  MHC I-dependent antigen presentation is inhibited by poliovirus protein 3A.

Authors:  S B Deitz; D A Dodd; S Cooper; P Parham; K Kirkegaard
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

2.  Herpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity.

Authors:  Mark A Brockman; David M Knipe
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

3.  Coxsackievirus expression of the murine secretory protein interleukin-4 induces increased synthesis of immunoglobulin G1 in mice.

Authors:  N M Chapman; K S Kim; S Tracy; J Jackson; K Höfling; J S Leser; J Malone; P Kolbeck
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

4.  Endogenous neosynthesis vs. cross-presentation of viral antigens for cytotoxic T cell priming.

Authors:  Stefan Freigang; Denise Egger; Kurt Bienz; Hans Hengartner; Rolf M Zinkernagel
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-31       Impact factor: 11.205

5.  Inhibition of protein trafficking by coxsackievirus b3: multiple viral proteins target a single organelle.

Authors:  Christopher T Cornell; William B Kiosses; Stephanie Harkins; J Lindsay Whitton
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

6.  Expression of brain-derived neurotrophic factor in the central nervous system of mice using a poliovirus-based vector.

Authors:  Qingmei Jia; Fengyi Liang; Seii Ohka; Akio Nomoto; Tsutomu Hashikawa
Journal:  J Neurovirol       Date:  2002-02       Impact factor: 2.643

7.  Expression of an antigenic adenovirus epitope in a group B coxsackievirus.

Authors:  K Höfling; S Tracy; N Chapman; K S Kim; J Smith Leser
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

8.  Using recombinant coxsackievirus B3 to evaluate the induction and protective efficacy of CD8+ T cells during picornavirus infection.

Authors:  M K Slifka; R Pagarigan; I Mena; R Feuer; J L Whitton
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

9.  Oral immunization with a live coxsackievirus/HIV recombinant induces gag p24-specific T cell responses.

Authors:  Rui Gu; Anae Shampang; Toufic Nashar; Manisha Patil; Deborah H Fuller; Arlene I Ramsingh
Journal:  PLoS One       Date:  2010-09-02       Impact factor: 3.240

10.  Packaging limits and stability of HIV-1 sequences in a coxsackievirus B vector.

Authors:  John P Miller; Yongzhi Geng; Hwee L Ng; Otto O Yang; Paul Krogstad
Journal:  Vaccine       Date:  2009-05-03       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.